$81 million was awarded by NIAID through four new contracts to support development of candidate HIV vaccines
On Sept. 29, 2003, $81 million was awarded by National Institute of Allergy and Infectious Diseases (NIAID) through four contracts to support development of candidate HIV vaccines. The awards were part of NIAID’s HIV Vaccine Design and Development Teams program, a public-private partnership that sought to accelerate HIV vaccine development.
The contract recipients were AlphaVAx Human Vaccines (Durham, NC), Epimmune (San Diego, CA), Novavax (Columbia, MD), and Progenics Pharma (Tarrytown, NY).
Tags:
Source: National Institutes of Health
Credit: Photo: Scanning electron micrograph of HIV-1 budding (in green) from cultured lymphocyte. This image has been colored to highlight important features; Multiple round bumps on cell surface represent sites of assembly and budding of virions. Courtesy: C. Goldsmith, Centers for Disease Control and Prevention.
